[PDF][PDF] CANTOS ushers in a new calculus of inflammasome targeting for vascular protection—and maybe more
Despite overwhelming basic science linking inflammation to the pathobiology of
atherothrombosis, the specific clinical evidence indicating cardiovascular benefits from anti-
inflammatory pharmacotherapy has been lacking. The CANTOS trial (Ridker et al., 2017a)
now provides the first largescale proof of concept that inflammasome targeting can reduce
cardiovascular events—and, surprisingly, lung cancer.
atherothrombosis, the specific clinical evidence indicating cardiovascular benefits from anti-
inflammatory pharmacotherapy has been lacking. The CANTOS trial (Ridker et al., 2017a)
now provides the first largescale proof of concept that inflammasome targeting can reduce
cardiovascular events—and, surprisingly, lung cancer.
Despite overwhelming basic science linking inflammation to the pathobiology of atherothrombosis, the specific clinical evidence indicating cardiovascular benefits from anti-inflammatory pharmacotherapy has been lacking. The CANTOS trial (Ridker et al., 2017a) now provides the first largescale proof of concept that inflammasome targeting can reduce cardiovascular events—and, surprisingly, lung cancer.
cell.com
